Background
==========

Domoic acid (DA) is an excitatory amino acid analogue of kainic acid (KA) that acts through glutamate receptors to elicit a rapid and potent excitotoxic response, resulting in prolonged receptor activation, tonic depolarization and neuronal hyperexcitability, excessive Ca^2+^ influx, and ultimately widespread neuronal loss \[[@B1],[@B2]\]. Several studies have reported that the toxicity of DA is mainly mediated by the alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)/KA receptor in immature and mature neurons and glia from rat cerebellum \[[@B3],[@B4]\]. Furthermore, Giordano et al. \[[@B5]\] reported that an AMPA/KA receptor antagonist, but not an N-methyl-~D~-aspartate (NMDA) receptor antagonist, prevents DA-induced apoptosis in primary cultures of granule cells from mouse cerebellum.

The induction of neuronal cell death by DA *in vitro* is mediated by an increase in the production of reactive oxygen species (ROS) \[[@B6]-[@B8]\]. ROS are known to stimulate a number of events and pathways that lead to apoptosis, including mitogen-activated protein kinase (MAPK) signal transduction pathways \[[@B9]\]. In neuronal cells, p38 MAPK is preferentially activated by environmental stress and inflammatory cytokines, and it has been shown to promote neuronal cell death *in vitro*\[[@B10]\]. A recent study demonstrated that DA-induced cell death in primary neuronal cultures involves activation of p38 MAPK, and antioxidants prevented p38 MAPK phosphorylation \[[@B11]\]. Collectively, these lines of evidence suggest that DA induces ROS generation followed by p38 MAPK phosphorylation *in vitro*. In some studies, the hippocampus has been identified as a target site with high sensitivity to DA-induced toxicity \[[@B2],[@B12],[@B13]\]. A recent study demonstrated that abnormal ROS levels in the hippocampus of DA-treated mice activate the stress-activated protein kinase/c-Jun amino-terminal kinase (SAPK/JNK) pathway *in vivo*\[[@B14]\], but no studies have investigated ROS-mediated p38 MAPK signal transduction pathways in the hippocampus after administration of DA.

The WD40 repeat present in some proteins is a small structural motif of approximately 40 amino acids, typically bracketed by glycine-histidine and tryptophan-aspartate (GH-WD) \[[@B15]\]. Repeated WD40 motifs form a domain called the WD domain that is involved in protein-protein interactions. Proteins with WD40 repeats have important roles in a variety of cellular functions such as cell growth, proliferation, apoptosis, and intracellular signal transduction \[[@B15],[@B16]\]. WD repeat-containing protein 35 (WDR35) is a novel member of this protein family \[[@B17],[@B18]\]. In a mouse mutation screen for developmental phenotypes, Mill et al. \[[@B18]\] identified a mutation in the WDR35 gene as a cause of midgestation lethality associated with abnormalities characteristic of defects in the Hedgehog signaling pathway. Recently, we cloned rat WDR35, also referred to as naofen \[[@B19]\]. Very recently, we have found that bupivacaine, a local anesthetic, increases intracellular ROS levels and activates p38 MAPK in mouse neuroblastoma Neuro2a cells, resulting in apoptosis via an increase in the expression of WDR35 (under revision).

In the present study, we identified and quantified DA in the brains of rats after intraperitoneal DA administration by using liquid chromatography/ion trap tandem mass spectrometry (LC-MS/MS) analysis. We also performed histological examinations of the hippocampus after intraperitoneal DA administration in rats and investigated the potential involvement of glutamate receptors, ROS, p38 MAPK, and WDR35 in DA-induced toxicity.

Results
=======

Identification and quantification of DA in the rat brain by LC-MS/MS analysis
-----------------------------------------------------------------------------

LC-MS/MS analysis was performed to confirm that intraperitoneally administered DA reached the brain. The peak of the DA standard was detected at a retention time of 8.3 min under the LC conditions used in this experiment, and the full-scan mass spectrum showed the exclusive presence of the \[M + H\]^+^ ion at *m/z* 312 (data not shown). The MS/MS product ion spectra of DA, obtained using the \[M + H\]^+^ ion at *m/z* 312 as precursor, showed three fragment ions at *m/z* 248, *m/z* 266, and *m/z* 294. As an example, an accumulated reconstructed ion chromatogram (Figure [1A](#F1){ref-type="fig"}) of the three product ions (*m/z* 312 → 248, 266, 294) and the MS/MS spectrum (Figure [1B](#F1){ref-type="fig"}) for a 10 ng/ml standard DA solution are shown. Representative LC-MS/MS analysis of a brain sample from a rat obtained at 30 min after intraperitoneal injection of 1 mg/kg DA shows the same retention time (8.3 min) as that of the standard DA (Figure [1C](#F1){ref-type="fig"}) and the presence of three diagnostic fragment ions (Figure [1D](#F1){ref-type="fig"}) with the ion abundance ratios fully consistent with those of the standard DA, thus confirming the presence of DA in this brain sample.

![**LC-MS/MS analysis of domoic acid.** Intraperitoneally administered DA (1 mg/kg) was identified and quantified in the rat brain by LC-MS/MS analysis. **(A)** Accumulated reconstructed ion chromatograms of the three product ions (*m/z* 312 → 248, 266, 294) having a retention time of 8.3 min and **(B)** MS/MS spectrum for a 10 ng/ml standard solution of DA. **(C)** A brain sample from a rat taken at 30 min after intraperitoneal DA administration (1 mg/kg) showing the same retention time as that of the standard DA and **(D)** the presence of three diagnostic fragment ions.](1471-2202-14-4-1){#F1}

Recovery tests were performed for quantification of the concentrations of DA in brain samples. The recovery of DA from brain samples spiked with 40 ng/g of DA was examined by calculating the ratio of the amount of analyte recovered after purification with the C18 cartridge column to the amount originally added. Overall recoveries and coefficients of variation were found to be satisfactory; these values were 84.4% and 11.0%, respectively (n = 3). The mean concentration of DA in rat brain samples obtained at 30 min after intraperitoneal administration of 1 mg/kg DA was 7.2 ± 0.75 ng/g (n = 3).

Histological examination of the CA1 region of rat hippocampus following DA administration
-----------------------------------------------------------------------------------------

Since LC-MS/MS analysis confirmed the distribution of intraperitoneally administered DA (1 mg/kg) to the brain, we carried out histological examinations of the CA1 region of the rat hippocampus at 24 hours after DA administration. Hematoxylin-Eosin staining showed no neurodegenerative changes such as neuronal shrinkage and cell dropout in the CA1 region after vehicle (saline) administration (Figure [2A](#F2){ref-type="fig"}). In contrast, neuronal shrinkage (arrow) and cell dropout (\*) were observed after DA administration (Figure [2B](#F2){ref-type="fig"}). As Giordano et al. \[[@B7]\] reported that DA induces apoptosis in primary cultures of mouse neurons, we used TUNEL staining to examine whether intraperitoneal DA at 1 mg/kg induces apoptosis in the CA1 region of the rat hippocampus. TUNEL-positive neurons were not observed after vehicle administration (Figure [2C](#F2){ref-type="fig"}). In contrast, at 24 hours after DA administration, a few TUNEL-positive neurons were observed (Figure [2D](#F2){ref-type="fig"}). Furthermore, at 5 days after DA administration, many TUNEL-positive neurons were observed (Figure [2E](#F2){ref-type="fig"}). Administration of 1 mg/kg DA significantly increased the percentage of TUNEL positive cells at 24 hours (8.3 ± 1.3%, *P* \< 0.05) and 5 days (19.0 ± 1.7%, *P* \< 0.001) compared with that of vehicle (1.7 ± 1.1%). Expression of WDR35 mRNA in the CA1 region was not detected by *in situ* hybridization after administration of vehicle (Figure [2F](#F2){ref-type="fig"}), whereas it was observed in the soma of neurons after administration of DA (Figure [2G](#F2){ref-type="fig"}). Furthermore, immunohistochemical staining for WDR35 showed weak expression of WDR35 in the soma and axons of neurons (enclosed by the dotted lines) after administration of vehicle (Figure [2H](#F2){ref-type="fig"}) and strong expression of WDR35 in the soma and axons of neurons (enclosed by the dotted lines) after administration of DA (Figure [2I](#F2){ref-type="fig"}). These results indicated that DA induces the expression of WDR35 mRNA and protein in neurons in the CA1 region of the hippocampus.

![**Histological examination of the CA1 region of rat hippocampus following DA administration.** Rats were treated intraperitoneally with either the control (vehicle) or DA (1 mg/kg). Tissues were collected at 24 hours (A-D, F-I) and 5 days (E) after treatment and prepared for histology. Images are shown at × 50 (A, B) and × 100 (C-I) magnification. To clarify cell type-specific staining and subcellular staining, insets show the same samples (indicated by arrowheads) at × 400 magnification. (A, B) Hematoxylin-Eosin staining **(A)** 24 hours after vehicle administration and **(B)** 24 hours after DA administration. Arrow indicates neuronal shrinkage; asterisk indicates cell dropout. (C-E) TUNEL staining **(C)** 24 hours after vehicle administration, **(D)** 24 hours after DA administration, and **(E)** 5 days after DA administration. Arrow indicates TUNEL-positive neuron. (F, G) *In situ* hybridization **(F)** 24 hours after vehicle administration and **(G)** 24 hours after DA administration. Arrow indicates positive staining for WDR35 mRNA. (H, I) Immunohistochemical staining for WDR35 **(H)** 24 hours after vehicle administration and **(I)** 24 hours after DA administration. Positive staining neurons are enclosed by dotted lines.](1471-2202-14-4-2){#F2}

Quantitative examination of WDR35 expression in rat hippocampus following DA administration
-------------------------------------------------------------------------------------------

Subsequently, real-time RT-PCR and western blotting analyses were performed to quantitatively examine the increase in WDR35 expression in the hippocampus following intraperitoneal DA administration. As shown in Figure [3A](#F3){ref-type="fig"}, administration of 1 mg/kg DA significantly increased WDR35 mRNA expression to a level 2.1-fold higher than the level observed after administration of vehicle. Furthermore, as shown in Figure [3B](#F3){ref-type="fig"}, administration of DA at 0.3 and 1 mg/kg significantly increased the expression of WDR35 protein compared with administration of vehicle. As the maximal effect was reached at 1 mg/kg DA, a dose of 1 mg/kg of DA was used for the following experiments.

![**Quantitative examination of WDR35 expression in rat hippocampus following DA administration.** (A, B) DA was administered to rats intraperitoneally at various doses. **(A)** WDR35 mRNA expression in hippocampal RNA preparations at 24 hours after DA administration was analyzed by qRT-PCR and expressed relative to the expression of GAPDH mRNA. **(B)** WDR35 protein expression in hippocampal homogenates at 24 hours after DA administration was analyzed by western blotting. (C, D) DA (1 mg/kg) was administered to rats intraperitoneally and WDR35 mRNA expression **(C)** and WDR35 protein expression **(D)** were determined in hippocampal samples collected at the times indicated after DA administration using the same methods as were used in (A) and (B). \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 (n = 4).](1471-2202-14-4-3){#F3}

As shown in Figure [3C](#F3){ref-type="fig"}, DA administration significantly increased the expression of WDR35 mRNA at 24 hours, when the level was 2.5-fold increased above the level at hour 0. Furthermore, as shown in Figure [3D](#F3){ref-type="fig"}, DA administration significantly increased the expression of WDR35 protein from 12 to 48 hours, with the maximal effect compared with hour 0 reached at 24 hours. These results showed that DA dose-dependently and time-dependently increases WDR35 expression in the rat hippocampus.

Examination of the relationships between AMPA/KA receptors, ROS and WDR35
-------------------------------------------------------------------------

Intraperitoneal injections of the selective glutamate receptor antagonists NBQX (AMPA/KA receptor antagonist, 3 mg/kg) and MK-801 (NMDA receptor antagonist, 3 mg/kg) were used to determine the types of glutamate receptors involved in the upregulation of WDR35 expression in the rat hippocampus at 24 hours after intraperitoneal DA administration (1 mg/kg). Analysis of immunoblots showed that NBQX significantly attenuated the DA-induced increase in WDR35 protein expression (Figure [4A](#F4){ref-type="fig"}). In contrast, MK-801 did not alter the DA-induced increase in WDR35 protein expression (Figure [4B](#F4){ref-type="fig"}). The antagonists alone had no effect on WDR35 protein expression.

![**Examination of the relationships between AMPA/KA receptors, ROS and WDR35.** Rats were administered glutamate receptor antagonists (3 mg/kg, i.p.) or edaravone (10 mg/kg, i.p.) at 1 hour before intraperitoneal administration of DA. WDR35 protein expression at 24 hours after DA administration in hippocampal samples from rats pretreated with **(A)** NBQX (AMPA/KA receptor antagonist), **(B)** MK-801 (NMDA receptor antagonist), or **(C)** edaravone (Ed, radical scavenger) was analyzed by western blotting. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 (n = 4).](1471-2202-14-4-4){#F4}

Several reports have shown that DA induces ROS generation *in vitro* via activation of the AMPA/KA receptor \[[@B6]-[@B8]\]. Therefore, we examined whether ROS might play a role in the DA-induced increase in WDR35 protein expression in the rat hippocampus by using the radical scavenger edaravone (10 mg/kg, i.p.) that has been shown to exert neuroprotective effects in animal models of several brain disorders \[[@B20]\]. Analysis of immunoblots showed that pretreatment with edaravone significantly attenuated the DA-induced upregulation of WDR35 (Figure [4C](#F4){ref-type="fig"}).

Examination of the relationships between AMPA/KA receptors, ROS and p38 MAPK
----------------------------------------------------------------------------

As Harper et al. \[[@B10]\] reported that ROS activates the p38 MAPK pathway, we then investigated whether intraperitoneal DA administration increases p38 MAPK phosphorylation in the rat hippocampus. Treatment with DA significantly increased p38 MAPK phosphorylation in immunoblots of hippocampal tissue samples (Figure [5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}). We also examined the effect of NBQX and edaravone on the DA-induced increase in p38 MAPK phosphorylation in the rat hippocampus. NBQX and edaravone significantly attenuated DA-induced p38 MAPK phosphorylation in immunoblots of hippocampal tissue samples (Figure [5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}). No significant change in the expression of p38 MAPK protein was observed. These results suggested that activation of the AMPA/KA receptor resulting in ROS generation followed by p38 MAPK phosphorylation might be involved in the DA-induced upregulation of WDR35.

![**Examination of the relationships between AMPA/KA receptors, ROS and p38 MAPK.** Rats were administered **(A)** NBQX (3 mg/kg, i.p.) or **(B)** edaravone (10 mg/kg, i.p.) at 1 hour before intraperitoneal administration of DA. Expression of p38 and phospho-p38 MAPK in rat hippocampus at 24 hours after intraperitoneal DA administration was analyzed by western blotting. \**P* \< 0.05, \*\**P* \< 0.01 and \*\*\**P* \< 0.001 (n = 3-7).](1471-2202-14-4-5){#F5}

Discussion
==========

LC-MS/MS has emerged as a powerful technique for the identification and quantification of natural products, such as toxins, in complicated matrices. In the present study, we applied this technique to the analysis of DA in the rat brain following an intraperitoneal dose of 1 mg/kg DA and confirmed the presence of DA (Figure [1](#F1){ref-type="fig"}) at a mean concentration of 7.2 ng/g tissue. A recent study using LC-MS/MS reported that the concentration of DA in fetal rat brains following an intravenous dose of 1 mg/kg DA in pregnant rats was stable at a mean of 8.12 ng/g tissue \[[@B21]\]. Although the experimental conditions differed greatly between this study and ours, the concentration of DA achieved in the brains of rats appeared to be comparable.

In the present study, neuronal shrinkage and cell dropout were observed in the CA1 region of the rat hippocampus at 24 hours after DA administration (Figure [2B](#F2){ref-type="fig"}). Similar neurodegenerative changes were also observed in rat brain in previous reports, although the doses of DA, route of administration of DA, and time course of measured effects were different in these studies: 2 mg/kg i.p. at 6--24 hours \[[@B22]\], 1.32 mg/kg i.p. at 8 days \[[@B23]\], and 0.75 mg/kg i.v. at 5--21 days \[[@B24]\]. As reported previously \[[@B8],[@B24]\], TUNEL-positive cells were observed following DA administration (Figure [2D](#F2){ref-type="fig"}, [2E](#F2){ref-type="fig"}). These observations suggest that in the present study, intraperitoneally administered DA induced neurodegenerative changes including apoptosis in the hippocampus.

Previously, we reported that enhanced WDR35 expression may mediate apoptosis in several animal models \[[@B25],[@B26]\]. As expected, expression of WDR35 was observed in neurons in the CA1 region of the rat hippocampus following DA administration (Figure [2G](#F2){ref-type="fig"}, [2I](#F2){ref-type="fig"}). Quantitative examination of WDR35 expression showed that WDR35 is upregulated in the rat hippocampus following DA administration. The increases in WDR35 mRNA and protein expression in the hippocampus were both dose-dependent (Figure [3A](#F3){ref-type="fig"}, [3B](#F3){ref-type="fig"}) and time-dependent (Figure [3C](#F3){ref-type="fig"}, [3D](#F3){ref-type="fig"}), suggesting that the increased expression of WDR35 may participate in the DA-induced neurodegenerative changes that were observed.

In studies *in vitro*, the toxicity of DA is mediated mainly via activation of the AMPA/KA receptor \[[@B3]-[@B5]\], whereas neurotoxicity is mediated secondarily via DA activation of the NMDA receptor/Ca^2+^ pathway \[[@B27],[@B28]\]. We examined the role of glutamate receptors in the DA-induced increase in WDR35 expression by using pharmacological blocking agents. We demonstrated that an AMPA/KA receptor antagonist (NBQX) significantly attenuated the DA-induced increase in WDR35 protein expression *in vivo* (Figure [4A](#F4){ref-type="fig"}), but an NMDA receptor antagonist (MK-801) did not (Figure [4B](#F4){ref-type="fig"}). These results suggest that the AMPA/KA receptor could play a role in DA-induced increases in WDR35 expression *in vivo*.

The induction of neuronal cell death by DA is mediated by increased ROS production \[[@B6]-[@B8]\]. In addition, kainic acid has been reported to stimulate ROS generation \[[@B6]\]. These observations led us to investigate the relationship between ROS and WDR35 expression by using a radical scavenger, edaravone. We demonstrated that edaravone significantly attenuated DA-induced WDR35 expression (Figure [4C](#F4){ref-type="fig"}), suggesting that DA-induced ROS production may increase the expression of WDR35 *in vivo*. In some studies, ROS have been shown to activate p38 MAPK, eventually causing apoptosis \[[@B10]\]. In the present study, we demonstrated that DA significantly increased p38 MAPK phosphorylation *in vivo*, and this effect was significantly attenuated by NBQX and edaravone (Figure [5A](#F5){ref-type="fig"}, [5B](#F5){ref-type="fig"}). Very recently, we found that the local anesthetic bupivacaine increases intracellular ROS levels and activates p38 MAPK, resulting in apoptosis via an increase in WDR35 expression in mouse neuroblastoma Neuro2a cells (under revision). Taking these observations into account, we speculate that in the present study, the increase in ROS production and activation of p38 MAPK by DA resulted in increased expression of WDR35 in the rat hippocampus.

Although several studies demonstrated that DA induces excitotoxic neuronal damage via activation of glutamate receptors \[[@B8],[@B24]\], the mechanistic cascades have not been investigated *in vivo*. In the present study, we provided the first evidence of the sequence of mechanisms for DA-induced toxicity by histological and biochemical examinations *in vivo*, in which DA activated the AMPA/KA receptor, and induced ROS production and p38 MAPK phosphorylation, resulting in an increase in the expression of WDR35. Our findings will be useful for future studies such as possible involvement of transcription factors of activating protein-1 (AP-1) and nuclear factor-kappa B (NF-κB) families in DA-induced toxicity, and detailed sequence of events including the role of WDR35.

Conclusions
===========

In conclusion, our results indicated that DA activated the AMPA/KA receptor, and induced ROS production and p38 MAPK phosphorylation, resulting in an increase in the expression of WDR35.

Methods
=======

Reagents
--------

Domoic acid (Sigma, St. Louis, MO, USA) was dissolved in saline solution (0.9% NaCl) at 1 mg/ml. The glutamate receptor antagonists, 2,3-dioxo-6-nitro-7-sulfamoylbenzo\[f\]quinoxaline (NBQX, Sigma, St. Louis, MO, USA) and dizocilpine maleate (MK-801, Tocris Bioscience, Ellisville, MO, USA) were dissolved in saline solution at 3 mg/ml. Edaravone (Tocris Bioscience, Ellisville, MO, USA) was dissolved in dimethyl sulfoxide at 10 mg/ml.

Animals and treatments
----------------------

Eight-week-old male Sprague--Dawley rats weighing approximately 300 g were purchased from SLC (Shizuoka, Japan) and habituated to the laboratory for 1 week before the experiments began. All procedures were approved by the Animal Care Committee of Aichi Medical University. All rats were kept in a climate-controlled room under 12/12-hour light--dark cycles with free access to food and tap water throughout the studies.

For the mass spectrometric analysis, rats were administered DA intraperitoneally at a dose of 1 mg/kg. Thirty minutes later, the rats were deeply anesthetized with pentobarbital sodium and were then perfused transcardially with cold phosphate-buffered saline (PBS). The brains were then removed and weighed. For histological examinations, rats were administered DA (1 mg/kg) or vehicle intraperitoneally. At 24 hours or 5 days after DA or vehicle administration, rats were deeply anesthetized with pentobarbital sodium and perfused transcardially with cold PBS followed by cold 4% paraformaldehyde in PBS, pH 7.2. The brains were removed and postfixed with 4% paraformaldehyde at 4°C for 24 h, then were dehydrated and embedded in paraffin. The paraffin blocks were stored at 4°C. Sections were cut at a thickness of 4 μm and processed for Hematoxylin-Eosin staining, *in situ* hybridization, immunohistochemistry, and TUNEL staining. For the qRT-PCR and western blot experiments, DA or vehicle administered rats were sacrificed by decapitation. The brains were rapidly excised, and hippocampi were rapidly dissected on an ice-cold dissection board. For dose--response studies, rats were administered DA intraperitoneally at doses of 0.3, 1, and 3 mg/kg and were sacrificed 24 hours later. For time-course studies, rats were sacrificed at 0, 6, 12, 24, and 48 hours after intraperitoneal administration of 1 mg/kg DA. Seizures \[[@B29]\] were observed in 3 mg/kg group. For pretreatment studies, NBQX, MK-801, and edaravone were administered to rats intraperitoneally at one hour before DA administration, and the rats were sacrificed at 24 hours after DA administration. Control rats received an equivalent volume of vehicle.

Preparation of extracts from rat brains for mass spectrometric analysis
-----------------------------------------------------------------------

Isolated rat brains were minced in 50% aqueous methanol (8 ml), homogenized, and centrifuged at 10,000 *g* for 20 min. The supernatant was passed through a cartridge column of Sep-Pak^®^ Plus C18 (Waters Co., Milford, MA, USA), and filtered with Amicon^®^ Ultra 0.5 ml 10 K centrifugal filter devices (Millipore Co., Billerica, MA, USA). The filtrate was subjected to LC-MS/MS analysis.

LC-MS/MS
--------

The LC separation was performed using an ACCELA HPLC system (Thermo Fisher Scientific, Waltham, MA, USA). Separation was accomplished with a TSK-GEL ODS-80Ts column (150 × 2.0 mm, Tosoh, Tokyo, Japan) at 30°C. Water containing 0.1% formic acid was used as eluent A, and acetonitrile containing 0.1% formic acid was used as eluent B. The LC elution gradient employed was: 0 to 5 min 100% A, 5 to 10 min eluent A decreased linearly to 50%, and 10 to 12 min 100% B. The eluent shifted back to 100% A and was held for 3 min to equilibrate the column for the next sample. The flow rate was 0.5 ml/min. The MS analysis was accomplished using a LTQ Velos spectrometer (Thermo Fisher Scientific, San Jose, CA, USA) equipped with a heated electrospray ionization (HESI) source. Positive ion HESI was chosen for the detection of DA. The source voltage was set at 3 kV, the capillary temperature was set at 350°C, and the tube lens offset was set at 15 V. The sheath gas flow rate was 35 (arbitrary units) and the auxiliary gas flow rate was 10 (arbitrary units). Full scan experiments were performed in the range *m/z* 50--1000. The total number of microscans was set at 1 and the maximum injection time at 10 ms. Subsequent MS/MS experiments were performed in the range *m/z* 85--400. The maximum injection time was set at 100 ms. Reproducible calibration curves for DA were obtained with correlation coefficients greater than 0.999 (known concentration versus analyte), and the curves were linear over the range of 0.2-10 ng/ml.

*In situ* hybridization
-----------------------

The sequence of the WDR35 probe was 5^′^AAGCACAAACTGAGGGTGATTTTCATCAGC-3^′^. Hybridization was performed at 105°C for 5 minutes and 50°C for 3 hours, with the probe diluted at 1:1000. The hybridization signal was amplified with the TSA Biotin System (PerkinElmer, Waltham, MA, USA) and visualized with DAB (Falma, Tokyo, Japan). The sections were counterstained with hematoxylin as described previously \[[@B25]\].

Immunohistochemical staining for WDR35
--------------------------------------

Rat brain sections were treated with 3% H~2~O~2~ in methanol for 30 min to inactive endogenous peroxidase, blocked at room temperature for 60 min with 4% goat serum albumin in PBS, and rinsed in 0.01 M PBS with 0.1% Tween20^®^ (PBS-T). Sections were then incubated at room temperature overnight with anti-WDR35 antibody (1:1000, Abcam, Cambridge, UK) in PBS-T. Immunohistochemical staining was done according to the manufacturer's protocol using a Vectastain ABC *Elite* kit (Vector Laboratories Inc., Burlingame, CA, USA) with the 3,3^′^-diaminobenzidine (DAB) reaction. Sections were counterstained with hematoxylin. Sections with no primary antibody were included as negative controls to verify the secondary antibody specificity.

Terminal deoxynucleotidyl transferase-mediated dUTP nick end-labeling (TUNEL) assay
-----------------------------------------------------------------------------------

TUNEL was performed using the ApopTag^®^ Plus In Situ Apoptosis Detection Kit (Chemicon International, Temecula, CA, USA) according to the manufacturer's instructions and visualized with the TSA Biotin System and DAB. The sections were counterstained with 0.5% methyl green (Wako Pure Chemicals, Osaka, Japan). Apoptotic and nonapoptotic cells were counted in three randomly chosen microscopic fields, and results are expressed as percentage of apoptotic cells ± S.E.

Quantitative real-time reverse transcriptase-polymerase chain reaction (qRT-PCR)
--------------------------------------------------------------------------------

Total RNA (1 μg) was extracted from rat hippocampus homogenate with TRIzol^®^ reagent (Invitrogen, Carlsbad, CA, USA) and reverse transcribed with a ReverTra Ace qPCR RT kit (Toyobo, Osaka, Japan). Quantitative RT-PCR was performed as described previously \[[@B26]\] with the ABI StepOne Plus real-time PCR system and a Taqman Gene Expression Assay (Applied Biosystems, Tokyo, Japan) according to the manufacturer's instructions. WDR35 mRNA levels were quantified relative to GAPDH mRNA levels, the internal control. The results are presented according to the ΔΔC~T~ method as ratios of the target to the internal control as described previously \[[@B26]\].

Western blot analysis
---------------------

Rat hippocampi were homogenized in lysis buffer \[62.5 mM Tris--HCl (pH6.8), 2.5% SDS, 10% glycerol\] containing a protease inhibitor cocktail (Roche Applied Sciences, Mannheim, Germany) and heated in boiling water for 5 min. After centrifugation, the supernatants were collected, and the protein concentration of samples was determined by the DC protein assay (Bio-Rad Laboratories, Hercules, CA, USA). Samples (30 μg protein) were mixed with 2-mercaptoethanol and Bromo Phenol Blue buffer, separated by SDS-PAGE, and transferred to PVDF membranes (Millipore Corporation, Billerica, MA, USA). The blots were incubated with rabbit antibodies against WDR35 (132kDa, 1:1000; Abcam, Cambridge, UK), p38 MAPK (43 kDa, 1:1000; Cell Signaling Technology, Danvers, MA, USA), phospho-p38 MAPK (43 kDa, 1:1000; Cell Signaling Technology) or GAPDH (37 kDa, 1:20,000; Cell Signaling Technology) followed by peroxidase-conjugated anti-rabbit IgG (1:5000; Zymed Laboratories, San Francisco, CA, USA). The apparent molecular weight of each protein was determined by BlueStar Prestained Protein Marker (Nippon Genetics Europe GmbH, Dueren, Germany). Detection was performed with the ECL Prime Western Blotting Reagent (GE Healthcare, Buckinghamshire, UK). Protein levels were quantified by densitometric scanning and expressed as the ratio to GAPDH, as described previously \[[@B30]\].

Statistical analysis
--------------------

All results were expressed as mean ± standard error of the mean (SEM). Data were analyzed for statistical significance with one-way analysis of variance (ANOVA), followed by post hoc analysis with the Bonferroni method. Differences were considered significant at *P* \< 0.05.
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